Eisler Capital (UK)’s Gilead Sciences GILD Stock Holding History

Eisler Capital (UK)’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$39.4M	Buy	470,099 +239,363	+104%	+$18.3M	0.18%	115
2024 Q2	$15.8M	Buy	230,736 +34,769	+18%	+$2.32M	0.1%	187
2024 Q1	$14.4M	Buy	195,967 +79,521	+68%	+$6.11M	0.12%	164
2023 Q4	$9.43M	Sell	116,446 -13,500	-10%	-$1.05M	0.07%	214
2023 Q3	$9.74M	Buy	129,946 +9,946	+8%	+$765K	0.06%	215
2023 Q2	$9.25M	Sell	120,000 -61,400	-34%	-$4.9M	0.07%	192
2023 Q1	$15.1M	Buy	+181,400	New	+$15M	0.15%	139
2022 Q2	–	Sell	-250,000	Closed	-$14.9M	–	445
2022 Q1	$14.9M	Buy	+250,000	New	+$16M	0.25%	103
2021 Q4	–	Sell	-250,000	Closed	-$17.5M	–	370
2021 Q3	$17.5M	Buy	+250,000	New	+$17.6M	0.68%	41

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Eisler Capital (UK)'s GILD Position: Q3 2024 in Review

Eisler Capital (UK) sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 4,265 shares — an estimated $325K sold.

Eisler Capital (UK) first reported a position in GILD in Q3 2021 and held it in 6 quarters. The position peaked at $9.8M in Q3 2023. 1,718 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

Eisler Capital (UK) reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
Eisler Capital (UK) sold 4,265 Gilead Sciences shares in Q3 2024, an estimated $325K.
Eisler Capital (UK) first reported a position in Gilead Sciences in Q3 2021 and held it in 6 quarters.
Eisler Capital (UK)'s Gilead Sciences position peaked at $9.8M in Q3 2023.
1,718 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on Eisler Capital (UK)'s 13F filing for Q3 2024, filed 14 Nov 2024.